Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with Cytokeratin 19-derived CYFRA21-1 and pathological staging

Clinica Chimica Acta

Volumn 419, Issue , 2013, Pages 57-61

  Chen, Qian ^a   Ge, Feng ^b   Cui, Wei ^a   Wang, Fei ^a   Yang, Zhuo ^a   Guo, Ye ^a   Li, Longyun ^a   Bremner, Ross Macrae ^c   Lin, Peter Ping ^d  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^d Cytelligen Corporation   (United States)

Author keywords

CTCs; CYFRA21 1; Enrichment; Lung cancer; Pathological staging

Indexed keywords

CYTOKERATIN 19; CYTOKERATIN 19 FRAGMENT; EPITHELIAL CELL ADHESION MOLECULE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CELL FUNCTION; CELL ISOLATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENRICHMENT CULTURE; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; LUNG DISEASE; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL SEPARATION; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING;

EID: 84874505680     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.01.015     Document Type: Article

References (34)

1. Sher Y.P., Shih J.Y., Yang P.C., et al. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Clin Cancer Res 2005, 11:173-179.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
3. Braun S., Naume B. Circulating and disseminated tumor cells. J Clin Oncol 2005, 23:1623-1626.
4. Pantel K., Brakenhoff R.H. Dissecting the metastatic cascade. Nat Rev Cancer 2004, 4:448-456.
5. Budd G.T., Cristofanilli M., Ellis M.J., et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403-6409.
6. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
7. Hayes D.F., Cristofanilli M., Budd G.T., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12:4218-4224.
8. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
9. Woelfle U., Sauter G., Santjer S., et al. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 2004, 10:2670-2674.
10. Paterlini-Brechot P., Benali N.L. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007, 253:180-204.
11. Went P.T., Lugli A., Meier S., et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004, 35:122-128.
12. Mikolajczyk S.D., Millar L.S., Tsinberg P., et al. Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol 2011, 2011:252361.
13. Wieskopf B., Demangeat C., Purohit A., et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest 1995, 108:163-169.
14. Broers J.L., Ramaekers F.C., Rot M.K., et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 1988, 48:3221-3229.
15. Alix-Panabieres C., Vendrell J.P., Slijper M., et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 2009, 11:R39.
16. Linder S. Cytokeratin markers come of age. Tumor Biol. 2007, 28:189-195.
17. Omary M.B., Ku N.O., Strnad P., Hanada S. Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest 2009, 119:1794-1805.
18. Bates J., Rutherford R., Divilly M., et al. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur Respir J 1997, 10:2535-2538.
19. Reinmuth N., Brandt B., Semik M., et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002, 36:265-270.
20. Pujol J.L., Molinier O., Ebert W., et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004, 90:2097-2105.
21. Barlesi F., Tchouhadjian C., Doddoli C., et al. CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy. Br J Cancer 2005, 92:13-14.
22. Ardizzoni A., Cafferata M.A., Tiseo M., et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006, 107:2842-2849.
23. Xu C., Liu J., Xing L., et al. Clinical significance of serum cytokeratin 19 fragment in the prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer. Chin. J. Lung Cancer 2010, 13:954-961.
24. Fleitas T., Martinez-Sales V., Gomez-Codina J., et al. Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer. Clin Transl Oncol 2010, 12:521-525.
25. Giovanella L., Ceriani L., Ghelfo A., Maffioli M. Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. Int J Biol Markers 2008, 23:54-57.
26. Hou J.M., Greystoke A., Lancashire L., et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 2009, 175:808-816.
27. Yu M., Stott S., Toner M., et al. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011, 192:373-382.
28. Wu C., Hao H., Li L., et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol 2009, 4:30-36.
29. Lin P., Li F., Zhang Y.W., et al. Calnuc binds to Alzheimer's beta-amyloid precursor protein and affects its biogenesis. J Neurochem 2007, 100:1505-1514.
30. Lin P., Fischer T., Weiss T., Farquhar M.G. Calnuc, an EF-hand Ca(2+) binding protein, specifically interacts with the C-terminal alpha5-helix of G(alpha)i3. Proc Natl Acad Sci U S A 2000, 97:674-679.
31. Devriese L.A., Bosma A.J., van de Heuvel M.M., et al. Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis. Lung Cancer (Ireland) 2012, 75:242-247.
32. Allard W.J., Matera J., Miller M.C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904.
33. Wimberger P., Heubner M., Otterbach F., et al. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Gynecol Oncol 2007, 107:331-338.
34. Dohmoto K., Hojo S., Fujita J., et al. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer 2001, 91:468-473.